Clinical Trial Update: A Pharmacogenomic Study of Candesartan in Heart Failure [Phase 4]

View source ↗

Summary

Phase 4 pharmacogenomic study of candesartan in heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Candesartan (candesartan)

Snippet

Sponsor: Montreal Heart Institute | Conditions: Heart Failure | Phase 4 | Status: COMPLETED